NPL 5

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference 141-446 PCT | | | FOR FURTHER ACTION | see Notification of Transmittal of International Search Rep (Form PCT/ISA/220) as well as, where applicable, item 5 below. | | | |
|--|--|--|---|--|--|--|--|
| International application No. PCT/US04/04112 | | | International filing date (day/mon 12 February 2004 (12.02.2004) | th/year) | (Earliest) Priority Date (day/month/year) 19 September 2003 (19.09.2003) | | |
| Applicant ANDRX LABS LLC | | | | | | | |
| This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. This international search report consists of a total of sheets. It is also accompanied by a copy of each prior art document cited in this report. 1. Basis of the Report | | | | | | | |
| | | anguage in which it was filed | , unless otherwise indicated under (| his item. | basis of the international application in the | | |
| b | | the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: | | | | | |
| | | contained in the international | al application in written form. | | | | |
| filed together with the international application in computer readable form. | | | | | | | |
| | | | | | | | |
| | | furnished subsequently to the | nis Authority in computer readable | form. | | | |
| | | the statement that the subse- international application as | | listing doe | s not go beyond the disclosure in the | | |
| | | the statement that the information been furnished. | nation recorded in computer readab | ole form is | identical to the written sequence listing has | | |
| 2. | | Certain claims were found | unsearchable (See Box I). | | | | |
| 3. | | Unity of invention is lacking (See Box II). | | | | | |
| 4. | With re | egard to the title, | | | | | |
| | M | the text is approved as subn | nitted by the applicant. | | | | |
| | | the text has been established | l by this Authority to read as follow | ws: | | | |
| 5. | With re | | | | | | |
| | \boxtimes | the text is approved as subn | nitte. ' the applicant. | | | | |
| | | | | | y as it appears in Box III. The applicant ch report, submit comments to this | | |
| 6. | The figure of the drawings to be published with the abstract is Figure No. | | | | | | |
| | | as suggested by the applicar | nt. | | None of the figures | | |
| | | because the applicant failed | to suggest a figure. | | | | |
| | | because this figure better ch | aracterizes the invention. | | | | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/04112

| A. CLASSIFICATION OF SUBJECT MATTER | | | | | | | | |
|---|---|-----------------|---|----------------------------------|--|--|--|--|
| IPC(7) : A61K 9/28, 9/16 | | | | | | | | |
| US CL : 424/474, 490 | | | | | | | | |
| According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED | | | | | | | | |
| | | | | | | | | |
| Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/474, 490 | | | | | | | | |
| | | | | | | | | |
| Documentat | ion contabad ather than minimum documentation to | h | | | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| Electronic d | ata base consulted during the international search (na | me of data | base and, where practicable, s | search terms used) | | | | |
| BRS | | | • • | , | | | | |
| | | | | | | | | |
| C. DOC | UMENTS CONSIDERED TO BE RELEVANT | | | | | | | |
| Category * | Citation of document, with indication, where a | ppropriate, | of the relevant passages | Relevant to claim No. | | | | |
| A | US 6,451,342 B2 (ADJEI et al.) 17 September 2002 (17.09.2002), see entire doc | | | 1-34 | | | | |
| | - | • | | | | | | |
| Α | US 6,524,621 B2 (ADJEI et al.) 25 February 2003 | (25.02.200 | 03), see entire document. | 1-34 | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | - | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| Further | documents are listed in the continuation of Box C. | | See patent family annex. | | | | | |
| | pecial categories of cited documents: | <u>"T"</u> | later document published after the inte | maticual filina data an anianisa | | | | |
| | · | • | date and not in conflict with the applic | | | | | |
| | defining the general state of the art which is not considered to be lar relevance | | principle or theory underlying the inve | | | | | |
| • | | "X" | document of particular relevance; the | claimed invention cannot be | | | | |
| "E" earlier ap | plication or patent published on or after the international filing date | | considered novel or cannot be consider | ed to involve an inventive step | | | | |
| | which may throw doubts on priority claim(s) or which is cited to | | when the document is taken alone | | | | | |
| establish t specified) | he publication date of another citation or other special reason (as | *Y" | document of particular relevance; the | | | | | |
| | | | considered to involve an inventive step combined with one or more other such | | | | | |
| "O" document | referring to an oral disclosure, use, exhibition or other means | | being obvious to a person skilled in the | | | | | |
| | published prior to the international filing date but later than the | "& " | document member of the same patent f | amily | | | | |
| priority d | ste claimed | | · | | | | | |
| Date of the a | ctual completion of the international search | Date of m | ailing of the international sear | phrter)(Mi | | | | |
| 26 July 2004 | (24.07.2004) | | ailing of the international | MOG CO04 | | | | |
| 26 July 2004 (26.07.2004) Name and mailing address of the ISA/US | | | d officer | | | | | |
| | Stop PCT, Attn: ISA/US | Audiolize | Authorized officer | | | | | |
| Commissioner for Patents | | | Authorized officer Robert M. Joynes 7. Roberts 457 | | | | | |
| P.O. Box 1450 | | | Telephone No. (571) 272-1600 | | | | | |
| | andria, Virginia 22313-1450 . (703) 872-9306 | retehnous | 2110. (211) 212-1000 | | | | | |
| | . () 0.0 2000 | | | | | | | |

Form PCT/ISA/210 (second sheet) (July 1998)

PATENT COOPERATION TREATY From the INTERNATIONAL SEARCHING AUTHORITY MARTIN P. ENDRES HEDMAN & COSTIGAN, P.C. 1185 AVENUE OF THE AMERICAS WRITTEN OPINION OF THE NEW YORK, NY 10036 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing 12 AUS 2004 (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION See paragraph 2 below 141-446 PCT International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/US04/04112 12 February 2004 (12.02.2004) 19 September 2003 (19,09,2003) International Patent Classification (IPC) or both national classification and IPC IPC(7): A61K 9/28, 9/16 and US Cl.: 424/474, 490 Applicant ANDRX LABS LLC 1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II **Priority** Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis (b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. 3. For further details, see notes to Form PCT/ISA/220.

Authorized officer

Telephone No. (571) 272-1600

Robert M. Joynes J. Roberts for

Facsimile No. (703) 872-9306
Form PCT/ISA/237 (cover sheet) (January 2004)

Name and mailing address of the ISA/ US

Commissioner for Patents P.O. Box 1450

Mail Stop PCT, Attn: ISA/US

Alexandria, Virginia 223 13-1450

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/04112

| Box N | o. I Basis of this opinion |
|----------------|--|
| | |
| 1. With it was | regard to the language, this opinion has been established on the basis of the international application in the language in which s filed, unless otherwise indicated under this item. |
| | This opinion has been established on the basis of a translation from the original language into the following language which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)). |
| 2. With claim | regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the ed invention, this opinion has been established on the basis of: |
| a. | type of material |
| | a sequence listing |
| | table(s) related to the sequence listing |
| b. | format of material |
| | in written format |
| | in computer readable form |
| c. | time of filing/furnishing |
| | contained in international application as filed. |
| | filed together with the international application in computer readable form. |
| | furnished subsequently to this Authority for the purposes of search. |
| | The second of th |
| 3. 🔲 | In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. |
| 4. Additi | ional comments: |
| | · |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/04112

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement Novelty (N) Claims 1-34 YES Claims NONE NO Inventive step (IS) Claims 1-34 YES Claims NONE NO Industrial applicability (IA) Claims 1-34 YES Claims NONE NO 2. Citations and explanations: Claims 1-34 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a pharmaceutical dosage form where in the controlled release core contains an antihyperglycemic drug and the coating contains a thiazolidinedione derivative wherein the coating layer is an immediate release layer. The cited references teach this two drug combination but the outside layer is not an immediate release composition where not less than 85% of the drug is released within 45 minutes but rather a controlled release layer that releases the drug over a longer period of time. Claims 1-34 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability as a pharmaceutical formulation because the subject matter claimed can be made or used in industry.